Radioisotope scanning using a gamma camera

H. BERRY, J. J. BARRETT, A. FORD-HUTCHINSON, AND E. B. D. HAMILTON

From the Departments of Rheumatology, Nuclear Medicine, and Chemical Pathology, King’s College Hospital, London SE5 9RS

SUMMARY Sixteen outpatients with rheumatoid arthritis took part in a placebo controlled double-blind crossover study. In addition to conventional measurements, a radioactive index was measured using a gamma camera that indicated a radioactive count over the measured joints and a comparable area of normal adjacent bone. This index showed poor correlation with other conventional measurements of change in the clinical trial.

Clinical trials of drugs that have an effect in rheumatology must use protocols that contain accepted measures of inflammation. This implies gross inflammation and change in inflammation. Any new measure must be validated by means of comparison with other measures in a clinical trial in order to assess its sensitivity. All the current clinical measures of pain and inflammation used are subjective to some degree except perhaps ring size, but it may well be unrealistic to expect much change in this measure in a short clinical trial although everyone continues to use this technique.

Hence there is still a need for objective criteria for assessment. Two techniques have been studied in the past—thermography and radioisotope scanning (Cosh et al., 1970; Dick et al., 1970). Thermography does not readily reflect change (Huskisson et al., 1973). Using a conventional counter, radioisotope studies, while they reflect gross inflammation, are poor reflectors of change (Berry et al., 1974). In this study an attempt has been made to increase the sensitivity of radioisotope scanning using a gamma camera which gives a print-out record of the scanning picture, indicating by colour the height of radioactive count.

Patients

Sixteen outpatients attending the department of rheumatology were taking part in a double-blind, controlled two-way crossover study in which they received new drug X or placebo. These were the patients with rheumatoid arthritis who would have conventionally received a nonsteroid anti-inflammatory drug. They were not receiving any other therapy except for rescue paracetamol as required.

Methods

Scanning technique

The patients received 10 mCi technetium phosphate complex (methylene diphosphonate) intravenously. 2 hours later the patients’ hands and wrists were scanned with an Elscint CEI-7 gamma camera with associated data processing, and a colour print-out was used to indicate the degree of isotope uptake. By this means it was possible to select the hottest joint and the activity was expressed by dividing it by background count. This result was called an isotope index. This test was carried out at the beginning of the study and at the end of the two treatment periods.

Trial measurements

During the study the following criteria were assessed: pain (by a 4-point scale and the visual analogue scale); early morning stiffness (in minutes); ring size (Geigy); articular index (Ritchie); and grip strength.

Results

Table 1 gives the clinical and isotopic results in response to drug X and to placebo. These show a small clinical deterioration during both treatment periods. The radioisotope index showed a slight improvement on placebo and a big deterioration on drug X. (Statistics are based on Wilcoxon matched pairs analysis.) Table 2 gives the correlation of changes over the whole study: there was only a poor overall correlation with articular index (r=0.55; P=0.05); grip strength (r=0.53; P=0.06) just failed to reach significance. There was no correlation with other parameters.
Table 1  Clinical and isotopic results (mean +SD)

<table>
<thead>
<tr>
<th>Radioisotope changes</th>
<th>Articular index</th>
<th>Morning stiffness</th>
<th>VAS</th>
<th>Ring size</th>
<th>Grip strength</th>
<th>Pain (4-point)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>2.9 ± 1.2</td>
<td>18 ± 5 ± 15.1</td>
<td>73 ± 96</td>
<td>10.2 ± 6.9</td>
<td>562 ± 47</td>
<td>577 ± 250</td>
</tr>
<tr>
<td>Drug X</td>
<td>2.8 ± 1.2</td>
<td>18.6 ± 15.8</td>
<td>144 ± 229*</td>
<td>12.4 ± 6.0</td>
<td>562 ± 47</td>
<td>578 ± 264</td>
</tr>
<tr>
<td></td>
<td>2.4 ± 1.0</td>
<td>16.3 ± 13.0</td>
<td>63 ± 98</td>
<td>9.7 ± 4.7</td>
<td>559 ± 46</td>
<td>619 ± 241</td>
</tr>
<tr>
<td></td>
<td>3.0 ± 1.1*</td>
<td>15.2 ± 14.2</td>
<td>78 ± 104</td>
<td>11.8 ± 6.2</td>
<td>561 ± 44</td>
<td>572 ± 252</td>
</tr>
</tbody>
</table>

*Indicates significant change P = <0.05. VAS = visual analogue scale.

Table 2  Correlation coefficients on differences using parametric linear regression analysis

<table>
<thead>
<tr>
<th>Articular index</th>
<th>Morning stiffness</th>
<th>VAS</th>
<th>Ring size</th>
<th>Grip strength</th>
<th>Pain (4-point)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>0.55</td>
<td>0.30</td>
<td>0.32</td>
<td>0.10</td>
<td>0.53</td>
</tr>
<tr>
<td></td>
<td>P=0.049</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug X</td>
<td>0.43</td>
<td>0.12</td>
<td>0.33</td>
<td>0.07</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>P=0.004</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo+Drug X</td>
<td>0.26</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.35</td>
</tr>
</tbody>
</table>

Discussion

An attempt has been made to improve the accuracy of radioisotope scanning using a gamma camera with a print-out that enables one to pick the joint with the highest radioactive count which reflects the most active joint. It was hoped that this would lead to a more accurate means of measuring not only gross inflammation, but change. However, such a technique would be of little value unless a good correlation could be shown between it and other measurements in current use in a clinical trial. Isotope scanning is time consuming and inconvenient for the patient, who has to wait 2 hours for the measurement and not all enjoyed the idea of a bolus of isotope being injected into them. Many with deformities dislike the pain associated with the measurement.

In this trial both placebo and drug X caused a small but consistent deterioration in the clinical status of the patients as judged by conventional measurement. The isotope measurement showed minimal improvement on placebo and a large deterioration on drug X. This result is different from the other measurement and it must be considered that it reflects a different effect of the drugs than what is normally measured as inflammation, if it is accepted that the other measurements do indeed show change in inflammation. There was a poor correlation with articular index but no other measurement (particularly ring size) showed any correlation. It must be concluded from this study that even this new modification of scanning, while it did show change, did not show change that was comparable with other measurements and it hardly seems worth the effort or the expense.

We thank Mrs M. E. Henderson and Mrs M. A. Howell for help with patients and administration, and Mrs S. Newton, Mrs P. Shields, and Miss J. Harris for help with isotope measurements.

References


Radioisotope scanning using a gamma camera.

H Berry, J J Barrett, A Ford-Hutchinson and E B Hamilton

Ann Rheum Dis 1978 37: 76-77
doi: 10.1136/ard.37.1.76

Updated information and services can be found at:
http://ard.bmj.com/content/37/1/76

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/